A rare case report of juvenile autoimmune overlap syndrome
Abstract
An autoimmune disorder occurs when the body's immune system turns against one’s own healthy body tissue, which may result in severe morbidity and mortality of the affectant. This may either result in the destruction of body tissue or changes in organ function,most of them involving multiple organ systems and are associated with presence of autoantibodies. The clinical presentation of this Connective tissue disorder (CTD) can range from an acute severe illness, to an insidious onset with gradual accumulation of symptoms and signs over weeks to months. The presence of multi-system involvement, evidence of inflammation and lack of any obvious cause should raise the possibility of CTD. Diagnosis is usually by specific physical findings like malar rash, Raynaud’s phenomenon, Gottron’s papules, pigmented lesions, photosensitivity, oral ulcers and supported by Presence of autoantibodies like anti-nuclear antibodies, anti-dsDNA etc.
Herewith we are presenting a rare case report of an Overlap Syndrome of Juvenile Dermatomyositis (JDM) with Sclerodactyly and Crest Syndrome
Key Words: Autoimmune Disease, Juvenile Dermatomyositis, Crest Syndrome, Sclerodactyly, Overlap SyndromeFull Text:
PDFReferences
Rider LG, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am. 1997 Aug. 23(3):619-55.
Maddison PJ. (1991). "Overlap syndromes and mixed connective tissue disease". Current Opinion in Rheumatology. 3 (6): 995–1000
Bohan A, Peter JB. Polymyositis and dermatomyositis. New Engl J Med. 1975;292:344–7
Symmons DP, Sills JA, Davis SM. The incidence of juvenile dermatomyositis: results from a nation-wide study. Br J Rheumatol. 1995 Aug. 34(8):732-6.
Engel AG, Arahata K, Emslie-Smith A. Immune effector mechanisms in inflammatory myopathies. Res Publ Assoc Res NervMent Dis. 1990. 68:141-57.
Reed AM, Stirling JD. Association of the HLA-DQA1*0501 allele in multiple racial groups with juvenile dermatomyositis. Hum Immunol. 1995 Nov. 44(3):131-5
Li CK, Varsani H, Holton JL, Gao B, Woo P, Wedderburn LR. MHC Class I overexpression on muscles in early juvenile dermatomyositis. J Rheumatol. 2004 Mar. 31(3):605-9.
Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005 May. 57(5):664-78.
Gerami P, Walling HW, Lewis J, Doughty L, Sontheimer RD. A systematic review of juvenile-onset clinically amyopathicdermatomyositis. Br J Dermatol. 2007 Oct. 157(4):637-44.
3.Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile Dermatomyositis with intravenous methylprednisolone and methotrexate. ClinRheumatol. 2000;19:138–41.
Fisler RE, Liang MG, Fuhlbrigge RC, et al. Aggressive management of juvenile Dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am AcadDermatol. 2002;47:505–11.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
An initiative of The Tamil Nadu Dr M.G.R. Medical University